Haemonetics Corporation (HAE) Hits Fresh High: Is There Still Room to Run?

Haemonetics rose 25.3% over the past month to a 52-week high of $128.83 and is up 59% year to date, after beating consensus EPS in each of the last four quarters; its latest EPS was $1.35 versus $1.30 expected, and revenue beat estimates by 3.15%. Zacks rates the stock #2 (Buy), with next-fiscal-year EPS and revenue forecasts of $5.73 and $1.49, respectively, although valuation is above peer averages at 24.1x forward EPS versus 21.3x. The article also highlights GE HealthCare, which beat consensus by 10.74% last quarter and gained 32.7% over the past month.

Analysis

The key question is whether estimate revisions can keep outrunning the valuation already embedded in HAE. The reported forward multiple premium is difficult to justify on the article’s modest sales and EPS growth outlook alone; the bull case therefore needs continued upward estimate revisions and evidence that earnings growth reflects durable operating improvement—not merely mix, share-count effects, or timing. Verify organic growth, margins, and the drivers of EPS before extrapolating the recent beats.

Near term, momentum and positive revisions can support further strength, so a fresh high is not by itself a short signal. Over the next 1–3 months, the asymmetry worsens if revisions stall: a premium multiple can contract even if HAE continues to grow. Over 6–18 months, the thesis depends on sustainable demand and execution, not the streak of quarterly surprises. A sustained close back below the cited $128.83 breakout area would be a useful tactical warning, not a standalone fundamental trigger.

GE HealthCare Technologies is cheaper on the article’s cited multiples, but it is not a clean hedge or direct operating substitute for HAE; the comparison is valuation context, not proof of relative mispricing. Treat the promotional article and its repeated, loosely specified estimates cautiously, and verify the revenue units and current consensus independently.

Key Decisions for Investors

• Existing HAE longs: avoid adding solely on the breakout; consider trimming into strength if the position has grown beyond risk limits. Reassess after the next report for organic revenue, margin trajectory, and whether forward estimates continue to rise.
• Tactical watch: if HAE closes back below the cited $128.83 breakout area and estimate revisions flatten, reduce exposure rather than averaging down. A renewed estimate-raising cycle with confirmed operating improvement would weaken this caution.
• GEHC may merit separate diligence as a lower-multiple alternative, but do not frame a long-GEHC/short-HAE pair as a tight hedge: their business exposures differ. Verify comparable growth, cash generation, and current valuations before sizing either leg.
• No standalone short or options trade is warranted from this article alone. The thesis is falsified if HAE delivers durable organic growth and margin improvement alongside further estimate increases; it is strengthened by guidance cuts, slowing revisions, or a failed breakout.